康艾注射液对乳腺癌患者化疗后生活质量的影响
发布时间：2018-07-17 03:38
【摘要】：目的:观察康艾注射液对乳腺癌患者化疗后生活质量的影响。方法:选取2015年12月01日至2016年12月01日期间于中国人民解放军武汉总医院肿瘤科就诊的60例女性乳腺癌根治术后患者作为研究对象。所有患者均拟行首次化疗,其ECOG评分在0-1分之间,入组前常规检查血常规、肝肾功能、心功能等大致正常,无明显化疗禁忌症。60例乳腺癌术后患者随机分成对照组(30例)和治疗组(30例),两组患者的临床分期、分子分型、年龄均无明显统计学差异(P0.05)。对照组采用吡喃阿霉素联合环磷酰胺方案化疗。治疗组在化疗前3天开始使用康艾注射液(60ml,静滴,1/日),连续治疗14天。两组患者均常规使用类似的止吐、护胃、护肝等对症治疗。于化疗后第10天分别检查两组患者血常规、肝肾功能、心功能,并用欧洲癌症研究及治疗组织生活质量核心量表测定化疗前后的生活质量评分。结果:(1)对照组治疗前与治疗后对比数据可见:患者的情绪功能在治疗后较治疗前显著降低(77.56±19.16 VS 70.12±16.20,P值0.023)。患者治疗后的疲倦、失眠、食欲减退、恶心和呕吐四项症状评分较治疗前显著升高(30.16±17.14 VS 41.56±19.12,P值0.019;16.14±22.45 VS 25.34±23.12,P值0.017;20.56±10.17VS 33.78±14.25,P值0.012;11.12±18.36 VS 27.78±20.16,P0.000)。(2)治疗组治疗前与治疗后对比数据可见:患者治疗后躯体功能、总体健康情况评分较治疗前升高(62.13±22.56 VS 57.12±21.36,P值0.035;61.41±23.56 VS 51.12±24.36,P值0.022),疲倦评分较治疗前下降(26.23±16.25 VS 32.23±15.54,P值0.028),食欲减退、恶心和呕吐的评分较治疗前明显升高(27.21±13.26 VS 20.14±12.10,P值0.025;18.65±21.34 VS 10.56±19.78,P值0.031)。(3)两组治疗后比较:治疗组的总体健康情况、躯体功能评分较对照组升高(61.41±23.56 VS 57.38±26.56,P值0.041;62.13±22.56 VS 55.86±23.42,P值0.038),疲倦、食欲减退及恶心和呕吐的评分较对照组降低(26.23±16.25 VS41.56±19.12,P值0.013;27.21±13.26 VS 33.78±14.25,P值0.008;18.65±21.34 VS 27.78±20.16,P值0.011)。(4)两组患者治疗期间出现II度或以上白细胞减少发生率分别为43.3%(11例)和13.3%(4例),差异具有统计学意义(P值0.037)。I度及以上肝功能损害发生率分别为40.0%(12例)和16.7%(5例),差异具有统计学意义(P值0.045)。Ⅱ度或以上血红蛋白减少、II度或以上血小板减少以及I度以上肾功能损害的发生率,两组间对比无显著的统计学差异(P0.05)。两组患者均未出现心脏毒性。结论:在吡喃阿霉素联合环磷酰胺化疗基础上加用康艾注射液能够提高乳腺癌患者的躯体功能、总体健康状况领域,改善化疗引起的疲倦、食欲减退、恶心和呕吐,虽然化疗后仍会出现或加重恶心、呕吐及食欲减退的症状,但程度明显轻于单纯化疗,同时可减少II度及以上白细胞减少、I度及以上肝功能损害的发生率,提高了患者的生活质量。
[Abstract]:Objective: to observe the effect of Kangai injection on quality of life of breast cancer patients after chemotherapy. Methods: 60 female breast cancer patients who were admitted to the Department of Oncology, Wuhan General Hospital of the Chinese people's Liberation Army from December 01, 2015 to December 1, 2016, were selected as the study objects. All patients were scheduled for the first time chemotherapy, and their ECOG scores ranged from 0 to 1. Routine examination of blood routine, liver and kidney function and cardiac function were normal before entering the group. No obvious chemotherapy contraindication. 60 cases of breast cancer patients were randomly divided into control group (30 cases) and treatment group (30 cases), the two groups of patients' clinical stage, molecular classification, age were not significantly different (P0.05). The control group was treated with adriamycin combined with cyclophosphamide regimen. The treatment group received Kangai injection 3 days before chemotherapy (60 ml, intravenous drip 1 / day) for 14 days. Patients in both groups were routinely treated with similar antiemesis, stomach care, liver protection and other symptomatic treatments. On the 10th day after chemotherapy, the blood routine examination, liver and kidney function, cardiac function were examined, and the quality of life scores before and after chemotherapy were measured with the European Cancer Research and treatment Organization quality of Life scale. Results: (1) compared with the control group before and after treatment, the emotional function of the patients decreased significantly after treatment (77.56 卤19.16 vs 70.12 卤16.20 P 0.023). The scores of fatigue, insomnia, anorexia, nausea and vomiting after treatment were significantly higher than those before treatment (30.16 卤17.14 vs 41.56 卤19.12 P 0.019 卤22.45 vs 25.34 卤23.12) P 0.017 20. 56 卤10.17 vs 33.78 卤14.25 P 0.012 11.12 卤18.36 vs 27.78 卤20.16 P0.000). (2 before and after treatment. The overall health score was higher than that before treatment (62.13 卤22.56 vs 57.12 卤21.36 P = 0.035 51.41 卤23.56 vs 51.12 卤24.36 P = 0.022), tiredness score decreased (26.23 卤16.25 vs 32.23 卤15.54 P = 0.028), appetite decreased. The scores of nausea and vomiting were significantly higher than those before treatment (27.21 卤13.26 vs 20.14 卤12.10 P = 0.025 卤18.65 卤21.34 vs 10.56 卤19.78 P = 0.031). (3). After treatment, the overall health status and somatic function score of the treatment group were significantly higher than those of the control group (61.41 卤23.56 vs 57.38 卤26.56 P = 0.041 卤62.13 卤22.56 vs 55.86 卤23.42 P 0.038). The scores of appetite loss and nausea and vomiting were lower than those of the control group (26.23 卤16.25 vs 41.56 卤19.12 P 0.013 卤27.21 卤13.26 vs 33.78 卤14.25 P 0.008 18.65 卤21.34 vs 27.78 卤20.16 P 0.011). (4). The incidence of leukopenia II or above during treatment was 43.3% (11 cases) and 13.3% (4 cases), respectively. The incidences of degree I and above liver function damage were 40.0% (12 cases) and 16.7% (5 cases), respectively (P = 0.045). There was no significant statistical difference between the two groups (P0.05). There was no cardiac toxicity in both groups. Conclusion: adriamycin combined with cyclophosphamide can improve the body function, overall health status, fatigue, anorexia, nausea and vomiting in patients with breast cancer. Although the symptoms of nausea, vomiting and anorexia are still present or aggravated after chemotherapy, they are significantly less severe than those of chemotherapy alone, and can also reduce the incidence of degree II and above leukopenia I and liver dysfunction. The quality of life of the patients was improved.
【学位授予单位】：湖北中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9
[Abstract]:Objective: to observe the effect of Kangai injection on quality of life of breast cancer patients after chemotherapy. Methods: 60 female breast cancer patients who were admitted to the Department of Oncology, Wuhan General Hospital of the Chinese people's Liberation Army from December 01, 2015 to December 1, 2016, were selected as the study objects. All patients were scheduled for the first time chemotherapy, and their ECOG scores ranged from 0 to 1. Routine examination of blood routine, liver and kidney function and cardiac function were normal before entering the group. No obvious chemotherapy contraindication. 60 cases of breast cancer patients were randomly divided into control group (30 cases) and treatment group (30 cases), the two groups of patients' clinical stage, molecular classification, age were not significantly different (P0.05). The control group was treated with adriamycin combined with cyclophosphamide regimen. The treatment group received Kangai injection 3 days before chemotherapy (60 ml, intravenous drip 1 / day) for 14 days. Patients in both groups were routinely treated with similar antiemesis, stomach care, liver protection and other symptomatic treatments. On the 10th day after chemotherapy, the blood routine examination, liver and kidney function, cardiac function were examined, and the quality of life scores before and after chemotherapy were measured with the European Cancer Research and treatment Organization quality of Life scale. Results: (1) compared with the control group before and after treatment, the emotional function of the patients decreased significantly after treatment (77.56 卤19.16 vs 70.12 卤16.20 P 0.023). The scores of fatigue, insomnia, anorexia, nausea and vomiting after treatment were significantly higher than those before treatment (30.16 卤17.14 vs 41.56 卤19.12 P 0.019 卤22.45 vs 25.34 卤23.12) P 0.017 20. 56 卤10.17 vs 33.78 卤14.25 P 0.012 11.12 卤18.36 vs 27.78 卤20.16 P0.000). (2 before and after treatment. The overall health score was higher than that before treatment (62.13 卤22.56 vs 57.12 卤21.36 P = 0.035 51.41 卤23.56 vs 51.12 卤24.36 P = 0.022), tiredness score decreased (26.23 卤16.25 vs 32.23 卤15.54 P = 0.028), appetite decreased. The scores of nausea and vomiting were significantly higher than those before treatment (27.21 卤13.26 vs 20.14 卤12.10 P = 0.025 卤18.65 卤21.34 vs 10.56 卤19.78 P = 0.031). (3). After treatment, the overall health status and somatic function score of the treatment group were significantly higher than those of the control group (61.41 卤23.56 vs 57.38 卤26.56 P = 0.041 卤62.13 卤22.56 vs 55.86 卤23.42 P 0.038). The scores of appetite loss and nausea and vomiting were lower than those of the control group (26.23 卤16.25 vs 41.56 卤19.12 P 0.013 卤27.21 卤13.26 vs 33.78 卤14.25 P 0.008 18.65 卤21.34 vs 27.78 卤20.16 P 0.011). (4). The incidence of leukopenia II or above during treatment was 43.3% (11 cases) and 13.3% (4 cases), respectively. The incidences of degree I and above liver function damage were 40.0% (12 cases) and 16.7% (5 cases), respectively (P = 0.045). There was no significant statistical difference between the two groups (P0.05). There was no cardiac toxicity in both groups. Conclusion: adriamycin combined with cyclophosphamide can improve the body function, overall health status, fatigue, anorexia, nausea and vomiting in patients with breast cancer. Although the symptoms of nausea, vomiting and anorexia are still present or aggravated after chemotherapy, they are significantly less severe than those of chemotherapy alone, and can also reduce the incidence of degree II and above leukopenia I and liver dysfunction. The quality of life of the patients was improved.
【学位授予单位】：湖北中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9
【参考文献】
相关期刊论文 前10条
1 肖敏;刘瑛;田武生;龚璐;;康艾注射液联合化疗对中晚期结直肠癌免疫功能及中医症候的影响[J];当代医学;2017年07期
2 王兰荣;王海存;曹e，
本文编号：2128834
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2128834.html
